<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02213887</url>
  </required_header>
  <id_info>
    <org_study_id>H14-01095</org_study_id>
    <nct_id>NCT02213887</nct_id>
  </id_info>
  <brief_title>Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications</brief_title>
  <acronym>PK-PPI</acronym>
  <official_title>A Pilot Study to Determine if Pantoprazole Modifies Steady-State Plasma Concentrations of Orally Administered Psychotropic Medications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this 9-day study is to determine if:

        1. Pantoprazole modifies the steady-state plasma concentrations of orally administered
           psychotropic medications including valproic acid, lithium, and second-generation
           antipsychotics (i.e., aripiprazole, asenapine, clozapine, lurasidone, olanzapine,
           paliperidone, quetiapine, risperidone, ziprasidone)

        2. Serum gastrin levels change within a week of starting or stopping pantoprazole
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals with psychiatric diagnoses may be predisposed to gastroesophageal reflux disease
      because of the widespread use of alcohol, cigarettes, and certain psychotropic drugs in this
      population. Consequently, they are often prescribed proton pump inhibitors. To our knowledge,
      no studies have been conducted to determine the effects of proton pump inhibitors on plasma
      levels of psychotropic drugs. The present clinical study will assess the effects of
      pantoprazole on the pharmacokinetics of valproic acid, lithium, and second-generation
      antipsychotics.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in steady-state plasma concentrations of psychotropic medication(s) at Days 2, 5, and 9.</measure>
    <time_frame>Days 1(baseline), 2 , 5, and 9</time_frame>
    <description>Pharmacokinetic outcome measures often require multiple measurement over time. On Day 1, baseline steady-state plasma concentration of psychotropic medication(s) will be determined. On Days 2, 5, and 9, steady-state plasma concentration of psychotropic medication(s) will be determined and compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting serum gastrin concentrations at Day 9.</measure>
    <time_frame>Days 1 (baseline) and 9</time_frame>
    <description>On Day 1, baseline fasting serum gastrin concentration will be determined. On Day 9, fasting serum gastrin concentration will be determined and compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Psychotic Disorders</condition>
  <condition>Gastroesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>Start Pantoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants have been diagnosed with gastroesophageal reflux disease but have not started pharmacological treatment.
Intervention: Days 2-8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stop Pantoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants have been taking pantoprazole for more than 8 weeks and are asymptomatic for gastroesophageal reflux disease.
Intervention: Days 2-8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>40 mg PO QAM</description>
    <arm_group_label>Start Pantoprazole</arm_group_label>
    <other_name>Pantoloc</other_name>
    <other_name>Protonix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>0 mg PO QAM</description>
    <arm_group_label>Stop Pantoprazole</arm_group_label>
    <other_name>Pantoloc</other_name>
    <other_name>Protonix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must be fluent in English

          -  Participants with a psychiatric diagnosis and currently treated with one or more of
             the following medications: valproic acid, lithium, or a second-generation
             antipsychotic (i.e., aripiprazole, asenapine, clozapine, lurasidone, olanzapine,
             paliperidone, quetiapine, risperidone, or ziprasidone)

          -  Participants on a stable dose of valproic acid, lithium, and/or a second-generation
             antipsychotic for a sufficient period of time that ensures they are at steady state

          -  Participants with symptoms of gastroesophageal reflux disease (GERD) that would
             benefit from treatment with pantoprazole or participants currently treated for GERD
             with pantoprazole for more than 8 weeks and are currently symptom free.

        Exclusion Criteria:

          -  Participants that are hypersensitive to pantoprazole

          -  Pregnant or lactating women

          -  Women of childbearing age not using reliable contraception

          -  Any postsurgical complications of the gastrointestinal tract that might impair
             absorption

          -  Clinically relevant abnormalities of laboratory parameters

          -  Participants treated with another acid suppressing agent (e.g., H2 receptor
             antagonists, antacids, alginates, etc)

          -  Participants treated with atazanavir, delavirdine, erlotinib, nelfinavir, and/or
             posaconazole
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ric M. Procyshyn, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alasdair Barr, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Honer, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Randall White, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UBC Hospital - Detwiller Pavilion</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2014</study_first_submitted>
  <study_first_submitted_qc>August 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2014</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Ric Procyshyn</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Drug Interactions</keyword>
  <keyword>Pantoprazole</keyword>
  <keyword>Proton Pump Inhibitors</keyword>
  <keyword>Psychotropic Drugs</keyword>
  <keyword>Antipsychotic Agents</keyword>
  <keyword>Aripiprazole</keyword>
  <keyword>Asenapine</keyword>
  <keyword>Clozapine</keyword>
  <keyword>Lurasidone</keyword>
  <keyword>Olanzapine</keyword>
  <keyword>9-hydroxy-risperidone</keyword>
  <keyword>Quetiapine</keyword>
  <keyword>Risperidone</keyword>
  <keyword>Ziprasidone</keyword>
  <keyword>Valproic Acid</keyword>
  <keyword>Lithium</keyword>
  <keyword>Gastrins</keyword>
  <keyword>Psychotic Disorders</keyword>
  <keyword>Gastroesophageal Reflux</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Psychotropic Drugs</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

